HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nail Diseases (Nail Disease)

Diseases of the nail plate and tissues surrounding it. The concept is limited to primates.
Also Known As:
Nail Disease; Disease, Nail; Diseases, Nail
Networked: 101 relevant articles (18 outcomes, 9 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Psoriasis (Pustulosis Palmaris et Plantaris)
2. Psoriatic Arthritis
3. Arthritis (Polyarthritis)
4. Pain (Aches)
5. Tinea (Ringworm)

Experts

1. Scher, Richard K: 5 articles (10/2021 - 02/2004)
2. Murdan, Sudaxshina: 3 articles (10/2018 - 11/2008)
3. Murdan, S: 3 articles (06/2018 - 03/2007)
4. Piraccini, Bianca Maria: 3 articles (09/2013 - 07/2006)
5. Krueger, Gerald G: 3 articles (12/2012 - 05/2007)
6. Mease, Philip J: 2 articles (05/2022 - 05/2007)
7. Nash, Peter: 2 articles (05/2022 - 05/2007)
8. Belikov, Andrey V: 2 articles (10/2021 - 07/2019)
9. Elewski, Boni: 2 articles (10/2021 - 12/2005)
10. Lipner, Shari R: 2 articles (10/2021 - 06/2018)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Nail Diseases:
1. Methotrexate (Mexate)FDA LinkGeneric
2. Infliximab (Remicade)FDA Link
3. Etanercept (Enbrel)FDA Link
4. tazarotene (Tazorac)FDA Link
5. ametantrone (HAQ)IBA
05/01/2021 - "Depressed patients had more frequently psoriatic nail disease (p = 0.02) and significant physical disability (HAQ-DI ≥ 0.5) (p < 0.01) and were more frequently in moderate or high disease activity according to DAPSA score (p = 0.01). "
07/01/2015 - "Clinical assessment (M0 and M6) included: BASDAI, HAQ, SPARCC, PASI and nail disease. "
04/01/2009 - "Efficacy assessments through week 24 included the American College of Rheumatology 20% improvement criteria (ACR20), the Psoriasis Area and Severity Index (PASI) in patients in whom at least 3% of the body surface area was affected by psoriasis at baseline, the Short Form 36 Health Survey (SF-36), the disability index of the Health Assessment Questionnaire (HAQ), the Nail Psoriasis Severity Index (NAPSI), the physician's global assessment of psoriatic nail disease, and enthesitis (using the PsA-modified Maastricht Ankylosing Spondylitis Enthesitis Score [MASES] index). "
04/01/2009 - "Significant improvement was observed for other major secondary end points (the HAQ and the SF-36), the NAPSI, the physician's global assessment of psoriatric nail disease, and the PsA-modified MASES index in each golimumab group compared with placebo. "
07/01/2022 - "Methods: Patients were recruited from the Chinese REgistry of Psoriatic ARthritis (CREPAR) between December 2018 and June 2021, and data were collected including the baseline demographic characteristics, various clinical manifestations (including arthritis, nail disease, comorbidities), laboratory tests[including erythrocyte sedimentation rate(ESR), C-reactive protein (CRP)], health assessment questionnaire (HAQ). "
6. Adrenal Cortex Hormones (Corticosteroids)IBA
7. Interleukin-17 (Interleukin 17)IBA
8. Interleukin-12 (IL 12)IBA
9. Antirheumatic Agents (DMARD)IBA
10. Ketoconazole (Nizoral)FDA LinkGeneric

Therapies and Procedures

1. Therapeutics
2. Lasers (Laser)
3. Biological Therapy
4. Dye Lasers
5. Surgical Amputation (Amputations)